2021年8月31日,中山大学肿瘤防治中心、华南肿瘤学国家重点实验室的谭静组在The Journal of Clinical Investigation在线发表了题为:Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in Preclinical Models of Advanced Ovarian Cancer的研究论文,该研究综合利用晚期卵巢癌模型构建、大规模测序及功能实验验...
2021年8月31日,中山大学肿瘤防治中心、华南肿瘤学国家重点实验室的谭静组在The Journal of Clinical Investigation在线发表了题为:Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in Preclinical Models of Advanced Ov...
2021年8月31日,中山大学肿瘤防治中心、华南肿瘤学国家重点实验室的谭静组在The Journal of Clinical Investigation在线发表了题为:Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in Preclinical Models of Advanced Ovarian Cancer的研究论文,该研究综合利用晚期卵巢癌模型构建、大规模测序及功能实验验...
ONLINE FIRST: Ovarian Cancer: MEK Inhibitor Selumetinib Active in Low-Grade Serous Carcinoma, but Mechanism Remains UnclearStockwellSerena
2021年8月31日,中山大学肿瘤防治中心、华南肿瘤学国家重点实验室的谭静组在The Journal of Clinical Investigation在线发表了题为:Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in Preclinical Models of Advanced Ovarian Cancer 的研究论文,该研究综合利用晚期卵巢癌模型构建、大规模测序及功能实验...
4例结直肠癌(CRC)和1例黑色素瘤患者治疗无效。 参考文献: https://www.onclive.com/view/raf-mek-inhibitor-vs-6766-plus-defactinib-under-exploration-in-recurrent-low-grade-serous-ovarian-cancer
MEK inhibitor 是一种酪氨酸激酶受体和细胞周期蛋白/CDK 复合物抑制剂,具有抗肿瘤活性,可用于研究肿瘤细胞增殖。 规格价格库存数量 1 mg¥ 848现货 5 mg¥ 2,120现货 10 mg¥ 2,960现货 25 mg¥ 4,790现货 50 mg¥ 6,680现货 1 mL x 10 mM (in DMSO)¥ 2,330现货 ...
4例结直肠癌(CRC)和1例黑色素瘤患者治疗无效。 参考文献: https://www./view/raf-mek-inhibitor-vs-6766-plus-defactinib-under-exploration-in-recurrent-low-grade-serous-ovarian-cancer
2022, Endocrine-Related Cancer Targeting kras in solid tumors: Current challenges and future opportunities of novel kras inhibitors 2021, Pharmaceutics MicroRNAs in ovarian cancer and recent advances in the development of microRNA-based biosensors 2020, Analyst Markers of MEK inhibitor resistance in low...
Pétigny-Lechartier, C. et al. The mTORC1/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor Trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737.Mol. Cancer Ther.16, 102–115 (2017). ...